Expression of claudins 1, 2, 3, 4, 5 and 7 in usual interstitial pneumonia and sarcoidosis Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
Late-breaking abstract: Relationship of aquaporin 1, 3 and 5 expression in lung cancer cells to cellular differentiation, invasive growth and metastasis potential Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Expression of transforming growth factors beta (1, 2, 3) and connective tissue growth factor in the peripheral lung from GOLD stage 1-2 COPD patients and smokers with normal lung function Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006
Inhibitor of DNA-binding (Id) – 1 and 3 proteins overexpression has impact on prognosis of lung adenocarcinoma Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Effect of 14-3-3 protein induction on oncogenic potential of BEAS-2B bronchial epithelial cells Source: International Congress 2019 – Biology of lung cancer Year: 2019
Human prohibitin 1 (hPH1) protein overexpression in COPD: preliminary results Source: Annual Congress 2009 - Highlighting the epithelial cell in lung disease: from COPD to cancer to acute lung injury Year: 2009
The expression rate of MAGE A1-6 and SSX4 in lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005
Expression of D2-40 in small cell lung carcinomas (SCLC); Association with lymphatic invasion(L.I), clinical parameters and prognosis Source: Annual Congress 2010 - New mechanisms and markers in human lung cancer Year: 2010
How to make me like your paper (part 2) Source: ERS Lung Science Conference 2021 Year: 2021
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
How to make me like your paper (part 1) Source: ERS Lung Science Conference 2021 Year: 2021
Handout EW1-3-5 Source: Amsterdam 2015 - Educational material Year: 2015
Use of 6-min (6M) and 12 min (12M) walking test (WT) for assessing the efficacy of formoterol (F) Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Eosinophils from healthy children (1-3 years) and adults express high levels of prostaglandin D2 receptor 2 (DP2) Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics Year: 2018
Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Handout EW2-4-6 Source: Amsterdam 2015 - Educational material Year: 2015
Handout EW7-9-11 Source: Amsterdam 2015 - Educational material Year: 2015